Genentech to Present Promising Long-term Hematology Data at ASH 2024

Genentech, a member of the Roche Group, has announced its participation in the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from December 7-10, 2024, in San Diego, California. The company will present over 40 abstracts covering nine different blood disorders, highlighting its dedication to improving patient outcomes in lymphoma. Their presentations will include long-term follow-up data on approved treatments like Polivy, Lunsumio, and Columvi, as well as new investigational combination therapies.

One of the key studies to be presented is the five-year data from the Phase III POLARIX study, which will be discussed in abstract #469. This study examines Polivy in combination with Rituxan, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for first-line diffuse large B-cell lymphoma (DLBCL). The findings suggest that this combination can lead to durable and lasting remissions, showing for the first time a positive trend in overall survival for people with this type of lymphoma, which has seen little advancement in treatment over the past 20 years.

Another critical presentation involves extended follow-up data from the pivotal GO29781 study of Lunsumio and the NP30179 study of Columvi, which will be covered in abstracts #4407 and #865, respectively. These studies show long-lasting remissions and recovery of the immune system post-treatment, supporting the use of fixed-duration bispecific antibodies for third-line or later follicular lymphoma (FL) and DLBCL.

Additionally, new data from a subcutaneous formulation of Lunsumio monotherapy will be presented for the first time. The pivotal Phase II GO29781 study (abstract #1645) demonstrates high rates of deep and durable responses with low incidence and severity of cytokine release syndrome in patients with third-line or later FL. Subcutaneous administration could enhance patient experience by offering shorter administration times while maintaining the benefits of fixed-duration, outpatient therapy.

The Phase III STARGLO study (abstract #5132) will reveal new patient-reported outcomes, indicating comparable health-related quality of life between different treatment arms, despite the higher median number of cycles in the Columvi combination arm. This, along with significant improvements in overall survival, supports the potential advantages for patients with second-line or later DLBCL.

Moreover, investigational studies on combinations of Polivy with bispecific antibodies Lunsumio and Columvi in relapsed or refractory DLBCL, including the Phase Ib/II NP39488 (abstract #988) and Phase II GO40516 (abstract #989) studies, add to the body of evidence supporting the efficacy of these novel treatments in earlier lines of therapy. These findings bolster the ongoing Phase III development of these combinations.

Genentech's presentations will also feature data on other significant medications, including Englumafusp alfa, Cevostamab, Venclexta, P-CD19CD20-ALLO1, P-BCMA-ALLO1, Hemlibra, and PiaSky. These presentations cover a range of topics, from the efficacy and safety of new treatments to patient outcomes and healthcare utilization models.

Overall, the breadth and depth of the data presented by Genentech at the ASH Annual Meeting underscore the company’s commitment to advancing treatment options and improving outcomes for patients with various blood disorders, particularly lymphomas. The findings presented will provide valuable insights into the long-term efficacy and safety of current treatments and promising new therapies under investigation.